DDInter735 DDInter1628
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomustine
Lomustine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomustine
Lomustine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomustine
Lomustine {u} (Compound) causes {v} (Side Effect) Contusion
Contusion {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Floxuridine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) binds {v} (Gene) RIOK2
RIOK2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Floxuridine {u} (Compound) downregulates {v} (Gene) PLK1
PLK1 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Floxuridine {u} (Compound) downregulates {v} (Gene) C2CD5
C2CD5 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) BLCAP
BLCAP {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) PLK3
PLK3 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Filgrastim {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cytarabine
Cytarabine {u} (Compound) downregulates {v} (Gene) TCERG1
TCERG1 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine (Compound) causes Contusion (Side Effect) and Contusion (Side Effect) is caused by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) binds RIOK2 (Gene) and RIOK2 (Gene) is upregulated by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine (Compound) downregulates PLK1 (Gene) and PLK1 (Gene) is bound by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine (Compound) downregulates C2CD5 (Gene) and C2CD5 (Gene) is downregulated by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates BLCAP (Gene) and BLCAP (Gene) is downregulated by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin (Compound) upregulates PLK3 (Gene) and PLK3 (Gene) is bound by Ruxolitinib (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine and Cytarabine (Compound) downregulates TCERG1 (Gene) and TCERG1 (Gene) is upregulated by Ruxolitinib (Compound)